Neo-Sequence 2: New drug combo for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment plan for advanced stomach cancer using chemotherapy, anti-angiogenesis therapy (to cut off tumor blood supply), and immunotherapy (to help your immune system fight cancer). The goal is to see if this combination works better before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced diffuse or mixed type stomach cancer confirmed by biopsy and imaging.
- Your cancer has not spread to distant organs and is stage T3-4NanyM0 (AJCC 8th edition).
- You have not had any prior anti-cancer treatment for stomach cancer.
- You are between 18 and 75 years old.
- You are in good general health (ECOG score 0 or 1) and have adequate organ function.
- You do not have serious medical conditions like uncontrolled infections, autoimmune diseases, or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial tests a new drug combination for people with advanced stomach or gastroesophageal junction cancer whose first treatment stopped working. The drugs are designed to help your immune system fight the cancer while chemotherapy attacks it directly.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, nab-paclitaxel and cadonilimab, as a second treatment for advanced stomach cancer that has spread to the belly lining. It may be an option if you haven't had any prior cancer therapy.
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.